Localised amyloid disease

From Wikilite

Share/Save/Bookmark
Jump to: navigation, search
Chapter

16

SECTION 2B - Diseases with monoclonal light chain deposition

Localised amyloid disease

Rather than being a systemic disease, amyloidosis may also present as a localised disease, where amyloid deposition is limited to a single organ. The specific area of the body affected depends upon the biochemical nature of the amyloid fibril protein and, as in systemic non-localised AL amyloidosis, light chain fragments may be involved. Localised AL amyloidosis may first be suspected on the basis of its location. Typical sites associated with localised AL amyloidosis include the brain, bladder, skin, urinary tract, conjunctiva, larynx and the tracheobronchial tree in the absence of systemic visceral dysfunction [1][2]. For patients with localised AL amyloidosis, localised therapy and life-long monitoring are necessary, although these patients have been shown to have a normal life expectancy [2].

Serum free light chains (sFLCs) have been evaluated in patients with localised amyloid disease attending the UK National Amyloidosis Centre, as presented in Table 16.1. An enlarged series of 235 cases, was reported by the same group in 2005 [3]. Of the 162/235 patients with tissue biopsy data available, the fibril type was classified as AL in 100 of cases (27% κ, 73% λ). The study concluded that localised AL amyloidosis is associated with a generally excellent prognosis.

Overall, elevated levels of sFLCs are less commonly observed in localised amyloidosis than in systemic AL amyloidosis and, even when present, the concentrations are lower. sFLC concentrations may therefore assist in distinguishing the different types of amyloid disease and also systemic from localised light chain amyloid disease.

Site of amyloid deposits
Number of patients Monoclonal proteins* Abnormal κ/λ ratios
Bone 7 3 (43%) 6 (88%)
Bladder 25 1 (4%) 3 (12%)
Bowel 10 4 (40%) 3 (30%)
Bronchial 13 2 (15%) 1 (8.0%)
Nodular pulmonary 13 3 (23%) 3 (23%)
Laryngeal 22 0 1 (4.5%)
Nasopharynx 16 1 (6%) 2 (13%)
Skin 18 2 (11%) 2 (11%)
Occular 10 2 (20%) 2 (20%)
Lymph Node 16 3 (19%) 5 (31%)
Miscellaneous 6 0 1 (17%)

Table 16.1. Frequency of monoclonal proteins in patients with localised amyloid disease. *Serum monoclonal proteins or light chain proteinuria identified by electrophoretic tests. (Courtesy of PN Hawkins).

Chapter 15 Back to Contents Page Chapter 17

References

  1. Biewend ML, Menke DM, Calamia KT. The spectrum of localized amyloidosis: a case series of 20 patients and review of the literature. Amyloid 2006;13:135-42 PMID: 17062379
  2. 2.0 2.1 Gertz MA. How to manage primary amyloidosis. Leukemia 2011 PMID: 21869840
  3. Goodman HJ, Bridoux F, Lachmann HJ, Gilbertson JA, Gallimore R, Joshi J, et al. Localised amyloidosis: Clinical features and outcomes in 235 cases. Haematologica 2005;90:1413a
Personal tools